Home  |  Contact

Cellosaurus OCI-Ly7 (CVCL_1881)

Cell line name OCI-Ly7
Synonyms OCI-LY7; OCI-LY-7; OCI-Ly-7; Oci-Ly-7; OCI-Ly 7; OCI-Ly07; OCILY7; Ly7; LY7
Accession CVCL_1881
Resource Identification Initiative To cite this cell line use: OCI-Ly7 (RRID:CVCL_1881)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: LL-100 blood cancer cell line panel.
Part of: MD Anderson Cell Lines Project.
From: Ontario Cancer Institute (OCI); Toronto; Canada.
Population: Caucasian.
Characteristics: Genetically heterogeneous, consists of 2 subclones (PubMed=27566572).
Doubling time: ~20-24 hours (DSMZ=ACC-688).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Array-based CGH.
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: Genome sequenced.
Omics: H3K9ac ChIP-seq epigenome analysis.
Omics: miRNA expression profiling.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
Sequence variations
  • Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=31160637; DSMZ=ACC-688).
HLA typing Source: PubMed=25960936
Class I
HLA-AA*01:01
HLA-BB*13
HLA-CC*04:01
Class II
HLA-DQDQA1*05:02,05:02
DQB1*03:09,03:09
HLA-DRDRB1*13:03,07:01

Source: DSMZCellDive=ACC-688
Class I
HLA-AA*01:01:01,01:01:01
HLA-BB*35:02:01,35:02:01
HLA-CC*04:01:01,04:01:01
Class II
HLA-DPDPA1*01:03:01,01:03:01
DPB1*03:01:01,17:01
HLA-DQDQA1*05:05:01,05:05:01
DQB1*03:01:01,03:01:01
HLA-DRDRA*01:02:02,01:02:02
DRB1*13:03:01,13:03:01
Genome ancestry Source: PubMed=30894373

Origin% genome
African0.44
Native American0.13
East Asian, North0
East Asian, South0.31
South Asian1.19
European, North69.58
European, South28.35
Disease Diffuse large B-cell lymphoma germinal center B-cell type (NCIt: C36080)
Diffuse large B-cell lymphoma (ORDO: Orphanet_544)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Male
Age at sampling 48Y
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; DepMap; DSMZ

Markers:
AmelogeninX,Y
CSF1PO12,13
D2S133822,24
D3S135814,17
D5S81811,12
D7S82010
D8S117913,15
D13S31711,12
D16S53912,13
D18S5120
D19S43314,16
D21S1129,31.2
FGA20
Penta D11,13
Penta E11,12
TH016,9.3
TPOX8,12
vWA15,18

Run an STR similarity search on this cell line
Web pages http://www.innovationbridge.com/uhn/diffuse-large-b-cell-lymphoma-cell-lines?categories=32&communities=5&forums=&organizations=&tags=
https://tcpaportal.org/mclp/
Publications

PubMed=3567358; DOI=10.1182/blood.V69.5.1307.1307
Tweeddale M.E., Lim B., Jamal N., Robinson J., Zalcberg J.R., Lockwood G., Minden M.D., Messner H.A.
The presence of clonogenic cells in high-grade malignant lymphoma: a prognostic factor.
Blood 69:1307-1314(1987)

PubMed=8574164; DOI=10.3109/10428199509059672
Chang H., Blondal J.A., Benchimol S., Minden M.D., Messner H.A.
p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's lymphoma cell lines.
Leuk. Lymphoma 19:165-171(1995)

PubMed=11807979; DOI=10.1002/gcc.10025
Mehra S., Messner H.A., Minden M.D., Chaganti R.S.K.
Molecular cytogenetic characterization of non-Hodgkin lymphoma cell lines.
Genes Chromosomes Cancer 33:225-234(2002)

PubMed=15126345; DOI=10.1158/0008-5472.CAN-03-3773
Ota A., Tagawa H., Karnan S., Tsuzuki S., Karpas A., Kira S., Yoshida Y., Seto M.
Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma.
Cancer Res. 64:3087-3095(2004)

PubMed=19278952; DOI=10.1182/blood-2009-01-202028
Li C., Kim S.-W., Rai D., Bolla A.R., Adhvaryu S., Kinney M.C., Robetorye R.S., Aguiar R.C.T.
Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma.
Blood 113:6681-6690(2009)

PubMed=19358282; DOI=10.1002/ijc.24351
Inagaki A., Ishida T., Yano H., Ishii T., Kusumoto S., Ito A., Ri M., Mori F., Ding J.-M., Komatsu H., Iida S., Ueda R.
Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC.
Int. J. Cancer 125:212-221(2009)

PubMed=20054396; DOI=10.1038/nature08638
Davis R.E., Ngo V.N., Lenz G., Tolar P., Young R.M., Romesser P.B., Kohlhammer H., Lamy L., Zhao H., Yang Y.-D., Xu W.-H., Shaffer A.L. III, Wright G., Xiao W.-M., Powell J.I., Jiang J.-K., Thomas C.J., Rosenwald A., Ott G., Muller-Hermelink H.-K., Gascoyne R.D., Connors J.M., Johnson N.A., Rimsza L.M., Campo E., Jaffe E.S., Wilson W.H., Delabie J., Smeland E.B., Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.C., Pierce S.K., Staudt L.M.
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Nature 463:88-92(2010)

PubMed=20628145; DOI=10.1182/blood-2010-05-282780
Green M.R., Monti S., Rodig S.J., Juszczynski P., Currie T., O'Donnell E., Chapuy B., Takeyama K., Neuberg D., Golub T.R., Kutok J.L., Shipp M.A.
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Blood 116:3268-3277(2010)

PubMed=23257783; DOI=10.1038/leu.2012.367
Wenzel S.-S., Grau M., Mavis C., Hailfinger S., Wolf A., Madle H., Deeb G., Dorken B., Thome M., Lenz P., Dirnhofer S., Hernandez-Ilizaliturri F.J., Tzankov A., Lenz G.
MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.
Leukemia 27:1381-1390(2013)

PubMed=23292937; DOI=10.1073/pnas.1205299110
Zhang J., Grubor V., Love C.L., Banerjee A., Richards K.L., Mieczkowski P.A., Dunphy C., Choi W., Au W.Y., Srivastava G., Lugar P.L., Rizzieri D.A., Lagoo A.S., Bernal-Mizrachi L., Mann K.P., Flowers C.R., Naresh K., Evens A.M., Gordon L.I., Czader M.B., Gill J.I., Hsi E.D., Liu Q.-Q., Fan A., Walsh K., Jima D., Smith L.L., Johnson A.J., Byrd J.C., Luftig M.A., Ni T., Zhu J., Chadburn A., Levy S., Dunson D.B., Dave S.S.
Genetic heterogeneity of diffuse large B-cell lymphoma.
Proc. Natl. Acad. Sci. U.S.A. 110:1398-1403(2013)

PubMed=23699601; DOI=10.1182/blood-2013-02-483727
Morin R.D., Mungall K., Pleasance E.D., Mungall A.J., Goya R., Huff R.D., Scott D.W., Ding J.-R., Roth A., Chiu R., Corbett R.D., Chan F.C., Mendez-Lago M., Trinh D.L., Bolger-Munro M., Taylor G., Hadj Khodabakhshi A., Ben-Neriah S., Pon J., Meissner B., Woolcock B., Farnoud N., Rogic S., Lim E.L., Johnson N.A., Shah S., Jones S.J.M., Steidl C., Holt R.A., Birol I., Moore R., Connors J.M., Gascoyne R.D., Marra M.A.
Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.
Blood 122:1256-1265(2013)

PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27566572; DOI=10.18632/oncotarget.11524
Quentmeier H., Pommerenke C., Ammerpohl O., Geffers R., Hauer V., MacLeod R.A.F., Nagel S., Romani J., Rosati E., Rosen A., Uphoff C.C., Zaborski M., Drexler H.G.
Subclones in B-lymphoma cell lines: isogenic models for the study of gene regulation.
Oncotarget 7:63456-63465(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x
Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.
The LL-100 panel: 100 cell lines for blood cancer studies.
Sci. Rep. 9:8218-8218(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line collections (Providers) DSMZ; ACC-688
Cell line databases/resources cancercelllines; CVCL_1881
Cell_Model_Passport; SIDM00459
Cosmic-CLP; 1659819
DepMap; ACH-001617
DSMZCellDive; ACC-688
Anatomy/cell type resources BTO; BTO:0006414
Biological sample resources BioSample; SAMN03473439
ENCODE; ENCBS006VZG
ENCODE; ENCBS040MJM
ENCODE; ENCBS062JSC
ENCODE; ENCBS121JKZ
ENCODE; ENCBS141AMI
ENCODE; ENCBS182NFY
ENCODE; ENCBS304FAI
ENCODE; ENCBS581USS
ENCODE; ENCBS699NWP
ENCODE; ENCBS865AAA
ENCODE; ENCBS866AAA
ENCODE; ENCBS886BJZ
CRISP screens repositories BioGRID_ORCS_Cell_line; 1398
Chemistry resources ChEMBL-Cells; CHEMBL4523533
ChEMBL-Targets; CHEMBL4523564
GDSC; 1659819
PharmacoDB; OCILY7_1187_2019
PubChem_Cell_line; CVCL_1881
Encyclopedic resources Wikidata; Q54931777
Experimental variables resources EFO; EFO_0006711
Gene expression databases ArrayExpress; E-MTAB-2706
ArrayExpress; E-MTAB-3610
ArrayExpress; E-MTAB-7721
ArrayExpress; E-MTAB-7722
GEO; GSM380135
GEO; GSM552453
GEO; GSM562825
GEO; GSM1035333
GEO; GSM1059809
GEO; GSM1374789
Polymorphism and mutation databases Cosmic; 1329092
Cosmic; 1517649
Cosmic; 1541903
Cosmic; 1629934
Cosmic; 1945199
Cosmic; 2276331
Progenetix; CVCL_1881
Proteomic databases PRIDE; PXD030304
Sequence databases EGA; EGAS00001000610
EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update30-Jan-2024
Version number40